BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35820898)

  • 1. MYCN protein stability is a better prognostic indicator in neuroblastoma.
    Yang Y; Zhao J; Zhang Y; Feng T; Yv B; Wang J; Gao Y; Yin M; Tang J; Li Y
    BMC Pediatr; 2022 Jul; 22(1):404. PubMed ID: 35820898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation Between
    Santiago T; Tarek N; Boulos F; Hayes C; Jeha S; Raimondi S; Rodriguez-Galindo C
    J Glob Oncol; 2019 Jul; 5():1-7. PubMed ID: 31365300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in
    Zhao M; Gu W; Liu F; Yu L; Shu Y; Liu L; Hu J; Liu Y; Tang H; Mao J
    Pediatr Dev Pathol; 2023; 26(2):124-132. PubMed ID: 36775958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
    Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
    BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
    Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H
    Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
    Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
    J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
    Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J
    Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Pediatr; 2021 Jun; 21(1):272. PubMed ID: 34116676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
    Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
    Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
    Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
    Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization (FISH) detection of MYCN oncogene amplification in neuroblastoma using paraffin-embedded tissues.
    Misra DN; Dickman PS; Yunis EJ
    Diagn Mol Pathol; 1995 Jun; 4(2):128-35. PubMed ID: 7551293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
    Kim EK; Kim S
    Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
    Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.